S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis
This study is designed to investigate the efficacy of S-1 plus cisplatin hyperthermic intraperitoneal chemotherapy for advanced gastric patients of gastric cytoreductive surgery (CRS)
Stage IV Gastric Cancer
DRUG: S-1 plus cisplatin HIPEC
PFS: Progression Free Survival, from randomization to disease progression or death, 2 years
OS: Overall Survival, from randomization to death from any cause, 5 years|Safety as measured by recording the subjects' Adverse Events from randomization to termination, Record the subjects' AEs from randomization to termination, 2 years
This project is a single-center, open clinical observation the safety and efficacy that stage IV limited peritoneal metastasis of gastric cancer patients accept S-1 plus hyperthermic intraperitoneal chemotherapy . With advanced gastric patients of confined to the peritoneal after CRS as the research object, with progression-free survival and overall survival, adverse events as the end points.